Prime Medicine PRME Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax at other companies
Other financials
Where this comes from
Reported directly by Prime Medicine in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Prime Medicine's debt securities, available-for-sale, accumulated gross unrealized loss, before tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Prime Medicine's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Prime Medicine (PRME) reported debt securities, available-for-sale, accumulated gross unrealized loss, before tax of $13K in Q1 2026.
- How has Prime Medicine's debt securities, available-for-sale, accumulated gross unrealized loss, before tax changed year-over-year?
- Prime Medicine's debt securities, available-for-sale, accumulated gross unrealized loss, before tax decreased by 13.3% year-over-year, from $15K to $13K.
- What is the long-term trend for Prime Medicine's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Over 3 years (2022 to 2025), Prime Medicine's debt securities, available-for-sale, accumulated gross unrealized loss, before tax has grown at a -80.2% compound annual growth rate (CAGR), from $384K to $3K.